![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTICAL COMPANY LAUNCH NEW RAPIDLY DISINTEGRATING ORAL ANTIPSYCHOTIC MEDICATION ABILIFY DISCMELT (ARIPIPRAZOLE)
BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTICAL COMPANY LAUNCH NEW RAPIDLY DISINTEGRATING ORAL ANTIPSYCHOTIC MEDICATION ABILIFY DISCMELT (ARIPIPRAZOLE)
August 18, 2006
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced the launch of ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets, a new oral form of the antipsychotic medication ABILIFY (aripiprazole) that disintegrates rapidly in the mouth. The U.S. Food and Drug Administration approved ABILIFY DISCMELT on June 7, 2006.
Bristol-Myers Squibb (http://www.bms.com/news/press/data/fg_press_release_6688.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct